EMA Authorised: Yuflyma (adalimumab) — Celltrion Healthcare Hungary Kft.

View source ↗

Summary

EMA authorised Yuflyma (adalimumab) as a biosimilar of adalimumab for several inflammatory and autoimmune diseases, including rheumatoid arthritis, psoriasis, a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Crohn Disease
• Hidradenitis Suppurativa
• Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis
• Uveitis

Drugs mentioned

• Yuflyma (adalimumab)

Snippet

Status: Authorised. Therapeutic area: Arthritis, Rheumatoid;Arthritis, Psoriatic;Psoriasis;Spondylitis, Ankylosing;Uveitis;Hidradenitis Suppurativa;Colitis, Ulcerative;Crohn Disease;Arthritis, Juvenile Rheumatoid. MAH: Celltrion Healthcare Hungary Kft.. Decision date: 30/01/2026